Céline Eiden, Delphine Capdevielle, Charlotte Deddouche, Jean-Philippe Boulenger, Jean-Pierre Blayac, Hélène Peyrière
Index: J. Addict. Med. 5(4) , 302-3, (2011)
Full Text: HTML
We report the case of a patient with chronic abuse of gamma-butyrolactone (GBL, 3 bottles per week for 4 months), who in the course of the management of acute agitation and hallucinations developed symptoms compatible with both neuroleptic malignant syndrome and GBL withdrawal symptoms.Some GHB withdrawal symptoms are similar to those of neuroleptic malignant syndrome, and the administration of antipsychotics might worsen the neurological condition of patients. So, it seems important to rapidly detect drugs taken by patients with mental agitation, to optimize management and minimize complications related to drugs.
| Structure | Name/CAS No. | Molecular Formula | Articles |
|---|---|---|---|
![]() |
Loxapine succinate
CAS:27833-64-3 |
C22H24ClN3O5 |
|
Investigation of the disposition of loxapine, amoxapine and ...
2012-01-01 [J. Pharm. Biomed. Anal. 58 , 83-93, (2012)] |
|
In vitro aerosol characterization of Staccato(®) Loxapine.
2011-01-17 [Int. J. Pharm. 403(1-2) , 101-8, (2011)] |
|
Inhaled loxapine for agitation revisited: focus on effect si...
2012-03-01 [Int. J. Clin. Pract. 66(3) , 318-25, (2012)] |
|
The pharmacoepidemiology of antipsychotics for adults with s...
2011-10-01 [Can. J. Psychiatry. 56(10) , 630-4, (2011)] |
|
Interaction of clozapine and its nitrenium ion with rat D2 d...
2011-02-01 [J. Comput. Aided Mol. Des. 25(2) , 163-9, (2011)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
